Earnings/(Loss) Per Common Share Attributable to Pfizer Inc. Common Shareholders

9 Months Ended

Oct. 01, 2023

Earnings/(Loss) Per Common Share Attributable to Pfizer Inc. Common Shareholders


The following presents the detailed calculation of EPS/(LPS):
	Three Months Ended				Nine Months Ended
(MILLIONS)	October 1, 2023		October 2, 2022		October 1, 2023		October 2, 2022
EPS/(LPS) Numerator


Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders	$	(2,394)	$	8,630	$	5,477	$	26,373
Discontinued operations––net of tax	12		(21)		11		4


Net income/(loss) attributable to Pfizer Inc. common shareholders	$	(2,382)	$	8,608	$	5,488	$	26,378




EPS/(LPS) Denominator
Weighted-average common shares outstanding––Basic	5,646		5,607		5,642		5,606
Common-share equivalents(a)	—		111		72		124
Weighted-average common shares outstanding––Diluted	5,646		5,718		5,714		5,729
Anti-dilutive common stock equivalents(b)	58		3		2		1

(a)For the three months ended October 1, 2023, due to the net loss attributable to Pfizer Inc. common shareholders, weighted average common-share equivalents of 56 million shares were not included in the computation of diluted LPS because their inclusion would have had an anti-dilutive effect.

(b)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.